recombinant mycobacterium tuberculosis fusion protein
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 17, 2023 (NCT06224608)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05899179 | Phase 3 | Aug 3, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Huazhong University of Science and Technology, Shenzhen Third People's Hospital |
| NCT06224608 | Phase 1 | Jan 17, 2023 | Capital Medical University, Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shenzhen Third People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1